Journal Article

Analytical Performance of the CEDIA<sup>®</sup> Cyclosporine PLUS Whole Blood Immunoassay

Anthony W. Butch and Alan M. Fukuchi

in Journal of Analytical Toxicology

Volume 28, issue 3, pages 204-210
Published in print April 2004 | ISSN: 0146-4760
Published online April 2004 | e-ISSN: 1945-2403 | DOI:
Analytical Performance of the CEDIA® Cyclosporine PLUS Whole Blood Immunoassay

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)


Show Summary Details


Cyclosporine A (CsA) is a potent immunosuppressive agent used in solid organ and bone marrow transplantation. Because of the narrow therapeutic range and variable pharmacokinetics, blood levels of CsA are routinely monitored. The performance of the CEDIA CsA PLUS whole blood immunoassay was evaluated on the Olympus AU400™, and results were compared to those obtained by high-performance liquid chromatography (HPLC), enzyme-multiplied immunoassay technique (EMIT), and fluorescence polarization immunoassay (FPIA). A total of 592 whole blood samples from patients receiving CsA were tested by each of the assays. CEDIA was linear from 25 to 2000 µg/t. Total imprecision ranged from 2.7% to 8.7% at CsA values between 48 and 1502 µg/L. Recovery of added CsA was within 10% of assigned values and was unaffected by bilirubin and lipemia. Metabolite cross-reactivity at 500 µg/L was 8.1% for AM1, 21.7% for AM4n, and 32.5% for AM9. Regression analysis revealed the following: HPLC = 0.93 · CEDIA − 21.2 (r = 0.975), EMIT = 1.08 · CEDIA − 25.2 (r = 0.982), and FPIA = 1.14 · CEDIA + 13.4 (r = 0.984). CEDIA has acceptable analytical performance for routine CsA monitoring. Advantages are the absence of an extraction step and an extended measuring range. The disadvantage is the high metabolite cross-reactivity; however, results were similar to EMIT.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.